Today on DrugResearcher.com   'Extreme PMT' gene not all the rage Big pharma enters stem cell domain to address safety, attrition Bayer, Biocon discuss potential R&D and outsourcing deal Eli Lilly: drug safety revolution 'within our grasp' Investors jump into PDL stock in hope of imminent buyout

Related Industry News   Granulation technology launched Price of FMC cellulose skyrockets CRO supremacy in clinical research raises concerns SAFC bets on drug conjugates with new manufacturing suite

Breaking News on Drug Discovery
Daily  Thursday 04 October 2007		Forward to a colleague

	Product Brochure Unique Process technology for drying very small quantities of API ProCepT's R&D Drying Technology for small quantities of API; SPRAY DRYING - NUTSCHE FILTER DRYING - AGITATED VACUUM DRYING - MICROWAVE DRYING. Fully instrumented and automated for Maximum of process knowledge with Minimum of API in a Minimum of time! Make use of the ProCepT lab... Click Here Access Full Stories 'Extreme PMT' gene not all the rage Researchers have, for the first time, unearthed a genetic variation that makes women more likely to suffer from the most extreme form of premenstrual tension or syndrome (PMT, PMS)... Read Big pharma enters stem cell domain to address safety, attrition Three of the world's biggest pharmaceutical companies have signed a landmark deal with the UK's government that will see them use stem cell technology to road-test the safety of new compounds... Read Bayer, Biocon discuss potential R&D and outsourcing deal German pharma firm Bayer is currently discussing with Indian company Biocon about a potential deal that would include the co-development of new biologics with an outsourcing element, according to Biocon... Read Eli Lilly: drug safety revolution 'within our grasp' The head of Eli Lilly has called for a reform of the US drug safety system, saying that an information revolution is 'within our grasp'... Read Investors jump into PDL stock in hope of imminent buyout Furious trading in shares of PDL BioPharma has taken place over the past couple of days as investors jumped in with both pockets open in the hope that a partner will soon be in the offing for the ailing firm... Read
	All News Headlines for: October | September | August
	Application Notes Separation of polar compounds A Mini-tutorial to HILIC The ZIC®-HILIC column is the ideal choice for separation of polar and hydrophilic compounds. Amino acids, bases, peptides, carbohydrates, plant extracts and other polar compounds have good retention on the column from SeQuant - "The Number One in HILIC"... Click Here
	Related Industry News Granulation technology launched Finland-based Atacama Labs has launched its proprietary technology system for developing solid oral dosage forms... Read Price of FMC cellulose skyrockets FMC BioPolymer has been forced to raise the price of its pharmaceutical grade cellulose by up to eight per cent to meet market pressures... Read CRO supremacy in clinical research raises concerns While contract research organisations (CROs) now dominate the clinical trials market, questions are being raised about the risks of 'commercialising' clinical studies, according to new research... Read SAFC bets on drug conjugates with new manufacturing suite SAFC has announced its plans to build a new high potency conjugation suite at its Missouri manufacturing plant in order to target pharma clients developing novel anti-cancer drug conjugates... Read Inside India: special series Clinical trials in India: 'The wind is blowing' An industry veteran gives Outsourcing-Pharma.com an update on the state of the contract research organisation (CRO) industry in India. Read Product Brochure A revolution in Sales Lead Generation! - Free Download Promote your products and technology towards our readers, and we'll build a detailed profile of each person who reads your presentation document... Download our FREE Smart Lead Generation brochure now!... Click Here Previous Headlines Sperm stopped in their tracks by vaginal gel contraceptive Forget diamonds, a new vaginal gel contraceptive could be the 21st Century girl's new best friend with the ability to be applied up to 18 hours before a naughty rendezvous... Read BMS takeover speculation mounts, again Investors in Bristol-Myers Squibb were in a frisson of excitement earlier this week as speculation mounted - not for the first time - that the firm could soon become the target of a major pharmaceutical acquisition... Read Tamiflu waste could create drug resistant flu viruses The excessive use of a popular influenza drug, and the associated build up of its waste in the environment, is heightening the risk of creating viruses in nature that are resistance to the therapy... Read PDL BioPharma for sale: one careful owner? PDL BioPharma's board has decided to scrap its restructuring plan and put the tormented company for sale, giving in to recent shareholders' pressure... Read Recordati adopts Orphan Europe Eighty-year-old Italian pharma company Recordati believes its future lies in rare diseases and has put its money where its mouth is by spending €135m on speciality firm Orphan Europe... Read Product Information - brochures, Web centers Separation of polar compounds - Application Notes Product Innovation Alerts - Free of Charge Indicate your research interests and receive alerts on relevant products and market innovations Analysis and instrumentation Assays and screening Cell culture & Equipment Chromatography Compounds and consumables Contract services (outsourcing) Drug discovery Genomics / Proteomics Informatics & IT Lab equipment & consumables Liquid handling and automation Liquid handling and sample preparation Production technologies Separation and purification

	Free Newsletters for Pharmaceuticals Access now !Choose from over 20 industry e-newsletters Access Decision News Media e-newsletters for the food, beverage & nutrition industries, click here
	Forward to a colleague

	To continue to receive this newsletter in your inbox, please add newsletter@DrugResearcher.com to your address book
	Update preferences | Change your email address | Unsubscribe
	Contact us: Advertising | Recruitment | Privacy policy | Terms & conditions | Feedback
	© 2007 - Decision News Media S.A.S - All Rights Reserved Le Belem - 355, rue Vendemiaire - 34000 Montpellier - France http://www.decisionnewsmedia.com